

Jae Yong Choi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8091718/publications.pdf>

Version: 2024-02-01

71
papers

1,942
citations

331259

21
h-index

264894

42
g-index

73
all docs

73
docs citations

73
times ranked

2597
citing authors

#	ARTICLE	IF	CITATIONS
1	Developmental complex trauma induces the dysfunction of the amygdala-mPFC circuit in the serotonergic and dopaminergic systems. <i>Biochemical and Biophysical Research Communications</i> , 2022, 605, 104-110.	1.0	1
2	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2245-2258.	3.3	27
3	Validation of Image Qualities of a Novel Four-Mice Bed PET System as an Oncological and Neurological Analysis Tool. <i>Journal of Imaging</i> , 2021, 7, 43.	1.7	3
4	Combined Model of Aggregation and Network Diffusion Recapitulates Alzheimer's Regional Tau-Positron Emission Tomography. <i>Brain Connectivity</i> , 2021, 11, 624-638.	0.8	8
5	Therapeutic Effects of Aripiprazole in the 5xFAD Alzheimer's Disease Mouse Model. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9374.	1.8	7
6	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease. <i>JAMA Neurology</i> , 2021, 78, 961.	4.5	148
7	Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, 335-344.	0.4	73
8	The Impact of Amyloid- β or Tau on Cognitive Change in the Presence of Severe Cerebrovascular Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 573-585.	1.2	10
9	Inhibition of Colony-Stimulating Factor 1 Receptor by PLX3397 Prevents Amyloid Beta Pathology and Rescues Dopaminergic Signaling in Aging 5xFAD Mice. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5553.	1.8	30
10	Evaluation of the neuroprotective effect of taurine in Alzheimer's disease using functional molecular imaging. <i>Scientific Reports</i> , 2020, 10, 15551.	1.6	23
11	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. <i>JAMA Neurology</i> , 2020, 77, 632.	4.5	80
12	Evaluation of the Neuroprotective Effect of Microglial Depletion by CSF-1R Inhibition in a Parkinson's Animal Model. <i>Molecular Imaging and Biology</i> , 2020, 22, 1031-1042.	1.3	26
13	Temporal trajectories of in vivo tau and amyloid- β accumulation in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2879-2886.	3.3	24
14	Effect of Short-Term LTE RF-EMF Exposure on Dopamine Signaling and Behaviors in Mice. <i>The Journal of Korean Institute of Electromagnetic Engineering and Science</i> , 2020, 31, 847-850.	0.0	0
15	Age dependency of mGluR5 availability in 5xFAD mice measured by PET. <i>Neurobiology of Aging</i> , 2019, 84, 208-216.	1.5	27
16	Effects of P-gp and Bcrp as brain efflux transporters on the uptake of [¹⁸ F]FPEB in the murine brain. <i>Synapse</i> , 2019, 73, e22123.	0.6	1
17	Preparing a ⁶⁸ Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	3
18	Progressive Tau Accumulation in Alzheimer Disease: 2-Year Follow-up Study. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1611-1621.	2.8	75

#	ARTICLE	IF	CITATIONS
19	ICâ€Pâ€164: MEDIAL TEMPORAL TAU CAN BE A PREDICTOR OF AMYLOIDâ€POSITIVITY IN MILD COGNITIVE IMPAIRMENT. <i>Alzheimer's and Dementia</i> , 2019, 15, P130.	0.4	0
20	ICâ€Pâ€163: TEMPORAL TRAJECTORIES OF IN VIVO TAU AND AMYLOIDâ€ β ACCUMULATION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P130.	0.4	0
21	¹⁸ F-flortaucipir uptake patterns in clinical subtypes of primary progressive aphasia. <i>Neurobiology of Aging</i> , 2019, 75, 187-197.	1.5	12
22	Predicted sequence of cortical tau and amyloid- β deposition in Alzheimer disease spectrum. <i>Neurobiology of Aging</i> , 2018, 68, 76-84.	1.5	39
23	A β pathology downregulates brain mGluR5 density in a mouse model of Alzheimer. <i>Neuropharmacology</i> , 2018, 133, 512-517.	2.0	25
24	Predominant subcortical accumulation of ¹⁸ F-flortaucipir binding in behavioral variant frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 66, 112-121.	1.5	15
25	Distinct patterns of amyloidâ€dependent tau accumulation in Lewy body diseases. <i>Movement Disorders</i> , 2018, 33, 262-272.	2.2	54
26	Effects of hypothyroidism on serotonin 1A receptors in the rat brain. <i>Psychopharmacology</i> , 2018, 235, 729-736.	1.5	6
27	Head to head comparison of [¹⁸ F] AV-1451 and [¹⁸ F] THK5351 for tau imaging in Alzheimerâ€™s disease and frontotemporal dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 432-442.	3.3	51
28	Off-Target ¹⁸ F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation. <i>Journal of Nuclear Medicine</i> , 2018, 59, 117-120.	2.8	70
29	P1â€382: COMPARISON OF AD PATHOLOGIES IN HYPERTENSIVE SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT AND CEREBRAL AMYLOID ANGIOPATHY. <i>Alzheimer's and Dementia</i> , 2018, 14, P445.	0.4	0
30	ICâ€Pâ€078: CLINICAL SIGNIFICANCE OF A/T/N SYSTEM IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT PATIENTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P69.	0.4	0
31	P1â€383: ¹⁸ F-FLORTAUCIPIR BINDING PATTERNS IN CLINICAL SUBTYPES OF PRIMARY PROGRESSIVE APHASIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P446.	0.4	0
32	Early Detection of A β Deposition in the 5xFAD Mouse by Amyloid PET. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-7.	0.4	23
33	Tau Positron Emission Tomography Imaging in Degenerative Parkinsonisms. <i>Journal of Movement Disorders</i> , 2018, 11, 1-12.	0.7	9
34	Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 53, 103-111.	1.5	66
35	¹⁸ F-AV-1451 PET Imaging in Three Patients with Probable Cerebral Amyloid Angiopathy. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 711-716.	1.2	18
36	¹⁸ F-â€AVâ€1451 binds to putamen in multiple system atrophy. <i>Movement Disorders</i> , 2017, 32, 171-173.	2.2	26

#	ARTICLE	IF	CITATIONS
37	Preliminary PET Study of ¹⁸ F-FC119S in Normal and Alzheimer's Disease Models. Molecular Pharmaceutics, 2017, 14, 3114-3120.	2.3	10
38	¹⁸ F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome. Neurology, 2017, 89, 1170-1178.	1.5	56
39	Synthesis and Preliminary Evaluation of ⁶⁸ Ga-NOTA-Biphenyl(RGDyK) for the Quantification of Integrin $\alpha v\beta 3$. Bulletin of the Korean Chemical Society, 2017, 38, 1415-1418.	1.0	0
40	[S20104]: IN VIVO CORTICAL SPREADING OF TAU AND AMYLOID. Alzheimer's and Dementia, 2017, 13, P540.	0.4	0
41	Subcortical ¹⁸ F-AV-1451 binding patterns in progressive supranuclear palsy. Movement Disorders, 2017, 32, 134-140.	2.2	109
42	[P1224]: ¹⁸ F-AV1451 PET IMAGING IN SUBCORTICAL VASCULAR COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P329.	0.4	0
43	[P2346]: EXCESSIVE NEOCORTICAL TAU ACCUMULATION IN DOWN SYNDROME. Alzheimer's and Dementia, 2017, 13, P754.	0.4	0
44	[ICP179]: PRINCIPAL COMPONENT ANALYSIS OF TAU PET IN ALZHEIMER'S DISEASE AND HEALTHY ELDERLY. Alzheimer's and Dementia, 2017, 13, P133.	0.4	0
45	[P1365]: PREDOMINANT SUBCORTICAL ¹⁸ F-AV-1451 BINDING IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2017, 13, P399.	0.4	0
46	[P1386]: DISTINCT TAU ACCUMULATION PATTERN IN DEMENTIA WITH LEWY BODY. Alzheimer's and Dementia, 2017, 13, P414.	0.4	1
47	[P2342]: ¹⁸ F-AV-1451 BINDS TO THE MOTOR-RELATED SUBCORTICAL GRAY AND WHITE MATTER IN CORTICOBASAL SYNDROME. Alzheimer's and Dementia, 2017, 13, P753.	0.4	0
48	In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Annals of Neurology, 2016, 80, 247-258.	2.8	375
49	P2232: TAU Burden and Cognition in Early-Onset Versus Late-Onset Alzheimer's Disease Spectrum. Alzheimer's and Dementia, 2016, 12, P711.	0.4	1
50	P3-263: TAU PET in Alzheimer's Disease and Mild Cognitive Impairment. , 2016, 12, P933-P933.		0
51	O4-07-04: In Vivo Cortical Spreading Pattern of TAU and Amyloid Pathology in the Alzheimer's Disease Spectrum. , 2016, 12, P349-P349.		1
52	Environmental enrichment enhances synaptic plasticity by internalization of striatal dopamine transporters. Journal of Cerebral Blood Flow and Metabolism, 2016, 36, 2122-2133.	2.4	31
53	Human Radiation Dosimetry of [18F]AV-1451(T807) to Detect Tau Pathology. Molecular Imaging and Biology, 2016, 18, 479-482.	1.3	13
54	Tau PET in Alzheimer disease and mild cognitive impairment. Neurology, 2016, 87, 375-383.	1.5	208

#	ARTICLE	IF	CITATIONS
55	Tau Accumulation in Primary Motor Cortex of Variant Alzheimer's Disease with Spastic Paraparesis. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 671-675.	1.2	13
56	Time and cost effective production of sodium [18F]fluoride using a dedicated automation module with disposable cassettes for GMP environment. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2016, 309, 983-987.	0.7	2
57	Biodistribution and Radiation Dosimetry of [18F]Mefway in Humans. <i>Molecular Imaging and Biology</i> , 2016, 18, 803-806.	1.3	3
58	Optimal timing of [18F]Mefway PET for imaging the serotonin 1A receptor in healthy male subjects. <i>Applied Radiation and Isotopes</i> , 2016, 107, 127-132.	0.7	3
59	P-Glycoprotein, not BCRP, Limits the Brain Uptake of [18F]Mefway in Rodent Brain. <i>Molecular Imaging and Biology</i> , 2016, 18, 267-273.	1.3	5
60	Relationship between dopamine deficit and the expression of depressive behavior resulted from alteration of serotonin system. <i>Synapse</i> , 2015, 69, 453-460.	0.6	24
61	[18F]FPEB and [18F]FDEGPECO comparative study of mGlu5 quantification in rodent brain. <i>Applied Radiation and Isotopes</i> , 2015, 98, 103-107.	0.7	4
62	18F-Mefway PET Imaging of Serotonin 1A Receptors in Humans: A Comparison with 18F-FCWAY. <i>PLoS ONE</i> , 2015, 10, e0121342.	1.1	14
63	Feasibility of Computed Tomography-Guided Methods for Spatial Normalization of Dopamine Transporter Positron Emission Tomography Image. <i>PLoS ONE</i> , 2015, 10, e0132585.	1.1	25
64	A Computed Tomography-Based Spatial Normalization for the Analysis of [¹⁸ F] Fluorodeoxyglucose Positron Emission Tomography of the Brain. <i>Korean Journal of Radiology</i> , 2014, 15, 862.	1.5	7
65	Acute physical stress induces the alteration of the serotonin 1A receptor density in the hippocampus. <i>Synapse</i> , 2014, 68, 363-368.	0.6	12
66	Determination of optimal acquisition time of [18F]FCWAY PET for imaging serotonin 1A receptors in the healthy male subjects. <i>Applied Radiation and Isotopes</i> , 2014, 89, 141-145.	0.7	4
67	Translational possibility of [¹⁸ F]Mefway to image serotonin 1A receptors in humans: Comparison with [¹⁸ F]FCWAY in rodents. <i>Synapse</i> , 2014, 68, 595-603.	0.6	3
68	Dopaminergic neuron destruction reduces hippocampal serotonin 1A receptor uptake of trans-[18F]Mefway. <i>Applied Radiation and Isotopes</i> , 2014, 94, 30-34.	0.7	4
69	Optimization of the radiosynthesis of [¹⁸ F]MEFWAY for imaging brain serotonin 1A receptors by using the GE TracerLab FX _{Pro} module. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 589-594.	0.5	8
70	Effective MicroPET imaging of brain 5-HT _{1A} receptors in rats with [¹⁸ F]MeFWAY by suppression of radioligand defluorination. <i>Synapse</i> , 2012, 66, 1015-1023.	0.6	13
71	Evaluation of dopamine transporters and D2 receptors in hemiparkinsonian rat brains in vivo using consecutive PET scans of [18F]FPCIT and [18F]fallypride. <i>Applied Radiation and Isotopes</i> , 2012, 70, 2689-2694.	0.7	13